Mesoridazine is a small footnote in the history of antipsychotic medication, but it is an instructive one. Once marketed as Serentil, it had a few decades of clinical use before regulatory action effectively ended its career — for the same cardiac safety reason that ended its parent drug's. Understanding mesoridazine helps explain how the field evaluates safety signals across structurally related medications.
Mesoridazine is the active metabolite of thioridazine, marketed separately for years as an antipsychotic, and discontinued in the US in 2004 after cardiac safety findings paralleled those of thioridazine.
What mesoridazine is
When the body metabolises thioridazine, one of the resulting compounds is mesoridazine — itself a pharmacologically active phenothiazine. In the 1970s and 1980s, mesoridazine was developed and sold as a separate antipsychotic on the rationale that the active metabolite was responsible for much of the parent drug's clinical effect. It was used for schizophrenia and, at lower doses, sometimes for acute agitation, alcohol-related psychosis, and other indications now treated very differently.
The receptor profile
Mesoridazine inherits much of thioridazine's pharmacology — modest D2 blockade, substantial histamine H1, alpha-adrenergic, and muscarinic activity, which translates into less EPS than high-potency typicals but more sedation, orthostasis, and anticholinergic burden. It is best thought of as a low- to mid-potency first-generation antipsychotic.
Why it was withdrawn
The same cardiac story that played out for thioridazine in 2000 played out for mesoridazine shortly after. Post-marketing data showed dose-related QT prolongation and case reports of torsades de pointes and sudden death. In 2002 the FDA added a boxed warning. Brand-name Serentil was discontinued in the US in 2004, and generic mesoridazine has not been routinely available since. Other countries took similar steps.
When a drug has a clear, dose-related cardiac signal and equally effective alternatives exist with smaller signals, regulators and clinicians tend to move away from the riskier option — even when many patients have done well on it.
Other side effects historically reported
- Sedation — substantial
- Orthostatic hypotension — common
- Anticholinergic effects — dry mouth, constipation, blurred vision, urinary hesitancy
- EPS — less than haloperidol or fluphenazine but possible
- Hyperprolactinemia — as with other D2 blockers
- Tardive dyskinesia — long-term risk
- Sexual side effects — including ejaculatory difficulties, similar to thioridazine
- NMS — rare
Where it sat in the older landscape
Before its withdrawal, mesoridazine was used in much the same niche as low- and mid-potency phenothiazines generally — chosen when sedation was useful, when EPS was a particular concern, or when a clinician was familiar with it from training. It never had the prescribing volume of thioridazine itself, and that may be part of why its disappearance from American formularies passed relatively quietly.
What the disappearance means today
For practical purposes, no new patient is started on mesoridazine in the US. Patients who were once on it have long since transitioned to other antipsychotics. The drug remains in the literature as a teaching example: an active metabolite developed as its own product, then withdrawn for reasons that affected an entire family of structurally similar phenothiazines.
What this teaches about prescribing today
Three takeaways are worth holding onto:
- Effectiveness is not the only consideration. A drug can work well and still lose its place when safer equivalents exist.
- Drug families share risks. The cardiac findings that ended thioridazine's first-line use applied directly to mesoridazine because the two share key pharmacology. The same principle is why prescribers think carefully about combining QT-prolonging drugs.
- Long-term surveillance matters. Both drugs were used for decades before the cardiac signal was characterised clearly enough to drive regulatory action. Modern post-marketing surveillance is one of the main reasons newer antipsychotics' risk profiles are clearer earlier.
If your medical history includes mesoridazine
Patients with longer psychiatric histories sometimes find references to mesoridazine in old records. If you were on it and are now on a different antipsychotic, the relevant question for your prescriber is usually whether your current regimen carries any of the same cardiac concerns — particularly if you are on multiple medications with QT effects, or if you have known cardiac risk factors. See our broader QT prolongation article.
The big picture
Mesoridazine's short story is one of pharmacological promise that ran into a real, quantifiable safety boundary. It is not a cautionary tale so much as an example of how medicine actually works — gathering evidence, weighing trade-offs, and accepting that the right answer in 1980 may be the wrong answer in 2005. The drug is gone from routine practice, but the reasoning behind its disappearance still shapes how every new antipsychotic is evaluated and prescribed today.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication.